These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?]. Stoppe G; Pirk O; Haupt M Gesundheitswesen; 2005 Jan; 67(1):20-6. PubMed ID: 15672302 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. Fuh JL; Wang SJ Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661 [TBL] [Abstract][Full Text] [Related]
5. [Comment on: Volz A, Monsch A.U., Zahno A., Wettstein A., Stähelin H.B., Grünig R.: What did Alzheimer disease cost Switzerland in 1998? A preliminary analysis]. Marko P Praxis (Bern 1994); 2000 Jul; 89(27-28):1165-6. PubMed ID: 10959206 [No Abstract] [Full Text] [Related]
6. [Cost-effectiveness of galantamine in a german context]. Happich M; Schweikert B; Mühlbacher A Psychiatr Prax; 2005 Apr; 32(3):142-50. PubMed ID: 15818530 [TBL] [Abstract][Full Text] [Related]
7. [Tacrine and "profitability"]. Nygaard HA Tidsskr Nor Laegeforen; 1997 Feb; 117(5):726. PubMed ID: 9102968 [No Abstract] [Full Text] [Related]
8. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. Lu S; Hill J; Fillit H Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386 [TBL] [Abstract][Full Text] [Related]
9. Study notes huge costs associated with Alzheimer's disease. Levenson D Rep Med Guidel Outcomes Res; 2002 Feb; 13(4):7-9. PubMed ID: 12434776 [No Abstract] [Full Text] [Related]
10. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease. Ballard C; Corbett A; Sharp S Expert Rev Neurother; 2011 Mar; 11(3):327-9. PubMed ID: 21375436 [No Abstract] [Full Text] [Related]
11. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Bosanquet N; Yeates A Pharmacoeconomics; 2006; 24(6):623-5; author reply 625-6. PubMed ID: 16761908 [No Abstract] [Full Text] [Related]
12. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia. Versijpt J J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049 [TBL] [Abstract][Full Text] [Related]
13. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Beier MT Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151 [TBL] [Abstract][Full Text] [Related]
14. Donepezil and Alzheimer's dementia. Earl-Slater A; Walley T Clin Perform Qual Health Care; 2000; 8(1):47-51. PubMed ID: 11183967 [No Abstract] [Full Text] [Related]
18. [A contribution to the current discussion on anti-dementia drugs in Germany]. Jessen F; Maier W Nervenarzt; 2007 May; 78(5):491-2, 494, 496-7. PubMed ID: 17106726 [TBL] [Abstract][Full Text] [Related]
19. [The use of acetylcholinesterase inhibitors in Alzheimer's disease]. Parnowski T Przegl Lek; 2001; 58 Suppl 3():2-6. PubMed ID: 11603170 [No Abstract] [Full Text] [Related]
20. The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London? Schneider LS Int J Geriatr Psychiatry; 2006 Jan; 21(1):9-13. PubMed ID: 16353164 [No Abstract] [Full Text] [Related] [Next] [New Search]